Drug Profile


Alternative Names: CGP 19835; CGP 19835A; Junovan; L-MTP-PE; Liposomal MTP-PE; Mepact; MLV 19835A; MTP-PE; Muramyltripeptide phosphatidylethanolamine

Latest Information Update: 25 Mar 2017

Price : $50

At a glance

  • Originator Novartis
  • Developer Medison Pharma; Takeda America Holdings
  • Class Antineoplastics; Drug conjugates; Ethanolamines; Immunoconjugates; Peptides
  • Mechanism of Action Macrophage stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Osteosarcoma
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Osteosarcoma
  • Discontinued HIV infections

Most Recent Events

  • 01 Oct 2014 Registered for Osteosarcoma in Brazil (IV)
  • 31 Oct 2013 No development reported - Phase-III for Osteosarcoma in USA (IV)
  • 31 Jul 2013 Registered for Osteosarcoma in Ukraine (IV)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top